Rothschild & Co Redburn initiated coverage of Agilent (A) with a Buy rating and $165 price target The firm sees the life science equipment market returning to “normalized growth” of 4%-6% over the medium term, bolstered by persistent innovation in analytical instrumentation. The firm likes Agilent’s “consistently strong” free cash flow. Its sensitivity analysis suggests the market is effectively assuming zero China revenue from 2030.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Agilent upgraded to Buy from Neutral at UBS
- Cautious Hold Rating for Agilent Amid New Product Launch and Market Uncertainties
- Agilent price target raised to $130 from $120 at Jefferies
- Agilent price target raised to $145 from $125 at Barclays
- Agilent announces insight series alarm resolution systems for airport security